These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19114680)

  • 21. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.
    Cohen-Wolkowiez M; Benjamin DK; Piper L; Cheifetz IM; Moran C; Liu P; Aram J; Kashuba AD; Capparelli E; Walsh TJ; Hope WW; Smith PB
    Clin Pharmacol Ther; 2011 May; 89(5):702-7. PubMed ID: 21412233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.
    Groll AH; Gullick BM; Petraitiene R; Petraitis V; Candelario M; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):596-600. PubMed ID: 11158761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Caspofungin Exposure in Patients in Intensive Care Units.
    van der Elst KC; Veringa A; Zijlstra JG; Beishuizen A; Klont R; Brummelhuis-Visser P; Uges DR; Touw DJ; Kosterink JG; van der Werf TS; Alffenaar JC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
    Würthwein G; Young C; Lanvers-Kaminsky C; Hempel G; Trame MN; Schwerdtfeger R; Ostermann H; Heinz WJ; Cornely OA; Kolve H; Boos J; Silling G; Groll AH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):536-43. PubMed ID: 22083471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children.
    Koo A; Sung L; Allen U; Naqvi A; Drynan-Arsenault J; Dekker A; Maloney AM; Dupuis LL
    Pediatr Infect Dis J; 2007 Sep; 26(9):854-6. PubMed ID: 17721388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
    Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
    Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.
    Groll AH; Wood L; Roden M; Mickiene D; Chiou CC; Townley E; Dad L; Piscitelli SC; Walsh TJ
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2554-63. PubMed ID: 12121932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats.
    Leshinsky J; McLachlan A; Foster DJR; Norris R; Barrs VR
    PLoS One; 2017; 12(6):e0178783. PubMed ID: 28575121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig.
    Roch A; Woloch C; Blayac D; Solas C; Quaranta S; Mardelle V; Castanier M; Papazian L; Sampol-Manos E
    Crit Care; 2011; 15(5):R219. PubMed ID: 21933398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.
    Sandhu P; Xu X; Bondiskey PJ; Balani SK; Morris ML; Tang YS; Miller AR; Pearson PG
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1272-80. PubMed ID: 15047529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety experience with caspofungin in pediatric patients.
    Zaoutis T; Lehrnbecher T; Groll AH; Steinbach WJ; Jafri HS; Maertens J; Ngai AL; Chow JW; Taylor AF; Strohmaier KM; Bourque M; Bradshaw SK; Petrecz M; Kartsonis NA
    Pediatr Infect Dis J; 2009 Dec; 28(12):1132-5. PubMed ID: 19779392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Brüggemann RJ; Lefrant JY; Roberts JA
    Clin Pharmacokinet; 2017 Sep; 56(9):1057-1068. PubMed ID: 28035589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
    Stone JA; Xu X; Winchell GA; Deutsch PJ; Pearson PG; Migoya EM; Mistry GC; Xi L; Miller A; Sandhu P; Singh R; deLuna F; Dilzer SC; Lasseter KC
    Antimicrob Agents Chemother; 2004 Mar; 48(3):815-23. PubMed ID: 14982770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections.
    Dinubile MJ; Strohmaier KM; Lupinacci RJ; Meibohm AR; Sable CA; Kartsonis NA
    Eur J Clin Microbiol Infect Dis; 2008 Aug; 27(8):663-70. PubMed ID: 18324427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths.
    Hall RG; Swancutt MA; Meek C; Leff R; Gumbo T
    Antimicrob Agents Chemother; 2013 May; 57(5):2259-64. PubMed ID: 23459494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.
    Sinnollareddy MG; Roberts JA; Lipman J; Akova M; Bassetti M; De Waele JJ; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Dimopoulos G;
    Crit Care; 2015 Feb; 19(1):33. PubMed ID: 25888060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.
    Song JC; Stevens DA
    Crit Rev Microbiol; 2016 Sep; 42(5):813-46. PubMed ID: 26369708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.